Dual FGFR-targeting and pH-activatable ruthenium-peptide conjugates for targeted therapy of breast cancer.
Franco Machado J, Sá M, Pires I, da Silva MT, Marques F, Coelho JAS, Mendes F, Piedade MFM, Machuqueiro M, Jiménez MA, Garcia MH, Correia JDG, Morais TS.
Franco Machado J, et al. Among authors: sa m.
Dalton Trans. 2024 May 7;53(18):7682-7693. doi: 10.1039/d4dt00497c.
Dalton Trans. 2024.
PMID: 38573236